Mannitol (Surgical — ICP/Osmotherapy)
Brand names: Mannitol 20%, Osmitrol
Mannitol is an intravenous osmotic diuretic used surgically and in neurocritical care for osmotherapy — chiefly to reduce raised intracranial pressure and cerebral oedema and to lower elevated intra-ocular pressure.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Being filtered but not reabsorbed by the kidney and largely confined to the extracellular space, mannitol raises plasma osmolality to draw water out of the brain and tissues and induces an osmotic diuresis.
Prescribing in practice
- Give through an in-line filter and assess renal function and volume status first, because mannitol can precipitate acute kidney injury, pulmonary oedema and dangerous fluid–electrolyte shifts — it is contraindicated in anuria, severe established renal failure, severe dehydration and decompensated cardiac failure.
- Inspect the solution and warm to redissolve any crystals before use, administer via a filtered set, and monitor serum osmolality and the osmolar gap to guide repeat dosing.
- Watch for rebound rises in intracranial pressure and correct hypovolaemia caused by the diuresis.
Monitoring
Monitor urine output, fluid balance, serum electrolytes, renal function and serum/calculated osmolality, alongside intracranial or intra-ocular pressure as appropriate.
Counselling the patient
- Usually given to critically ill or anaesthetised patients; explain to relatives it is a drip used to reduce pressure on the brain or eye.
- Where the patient is awake, mention it increases urine output markedly.
Evidence & guidelines
Mannitol is an established osmotherapy agent in neurosurgical and neurocritical-care guidance for raised intracranial pressure; the SPC details its renal, cardiac and electrolyte cautions.
Reference: NICE NG158 (Head Injury); Neurocritical Care Society Guidelines 2023; ESA Perioperative Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- POSSUM Score for Surgical Morbidity and Mortality · Perioperative Risk
- SORT (Surgical Outcome Risk Tool) · Perioperative Risk
- ASA Physical Status Classification · Perioperative Risk
- Caprini Score for VTE Risk (2005) · VTE Risk
- EuroSCORE II · Surgical Risk
- Thakar Score for AKI after Cardiac Surgery · Surgical Risk
- Major Trauma — Primary Survey (ATLS) · ATLS 10th Edition; JRCALC; NICE NG39
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Burns — TBSA Estimation & Fluid Resuscitation · British Burn Association; EMSB; RCEM 2024
- Lower Gastrointestinal Bleed · NICE; BSG; ACPGBI — Commissioning Guide
- Acute Pancreatitis · NICE; IAP/APA; ACPGBI — CG104
- Hypertrophic Pyloric Stenosis · BAPS / RCPCH